Announcements Trials
Browse Landscape

Phase

Phase NA 21Phase EARLY_PHASE1 1Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Thoracic 1Myeloid 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Urogenital Neoplasms 1Lung Neoplasms 1Colitis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 156Carboplatin 146Cisplatin 129Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 68Docetaxel 61Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33130-nm albumin-bound paclitaxel 26Radiosurgery 25fludarabine 23Ipilimumab 23Irinotecan 21Taxes 20Radiation 20Oxaliplatin 20Magnetic Resonance Spectroscopy 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Practice Guidelines as Topic × Thoracic × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡